Both rosuvastatin 10/20 mg and atorvastatin 10/20 mg were well tolerated, with a similar incidence of treatment-emergent adverse events. The most common AEs at 6 weeks were headache, back pain, and myalgia and the most common AEs at 12 weeks were myalgia, arthralgia, and back pain. The majority of AEs were of a mild-to-moderate intensity.1

There were no reported cases of rhabdomyolysis or acute renal failure. Clinically important elevations in alanine aminotransferase (>3x ULN) occurred in one patient (rosuvastatin 10/20 mg). One patient in the atorvastatin 10/20 mg group experienced CK >10 ULN without muscle symptoms and myalgia was associated with CK>10xULN in one patient in the rosuvastatin 10/20 mg group, which was indicative of myopathy.1

Reference

1. Stalenhoef AFH et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. Eur Heart J. 2005;26: 2664–2672